India, Nov. 17 -- NRx Pharmaceuticals, Inc. (NRXP) reported third-quarter 2026 results and outlined its transition from a development-stage biotechnology company to a commercial-stage business following the FDA approval of its first product, preservative-free ketamine.

The newly approved product received FDA approval ahead of its November 10, 2026 GDUFA goal date, and NRx has already begun commercialization efforts with a 17-person sales team targeting hospitals and purchasing organizations. The company said it has received its first order, with product shipments expected to begin by January 2027.

The company believes the initial U.S. market opportunity for preservative-free ketamine is approximately $400 million annually, with the potent...